Raclopride
Research News and Information

Sunday, November 22, 2009

Ex vivo [11C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro.

30 Oct 2009 Dopamine (DA) D2 receptor supersensitivity has been linked to an increase in the density of the D2 high-affinity state as measured in vitro. The two- affinity-state model of the D2 receptor predicts that the ex vivo specific binding of ... Read more...

Differential effects of topiramate on prefrontal glutamatergic transmission when combined with raclopride or clozapine.

29 Sep 2009 Treatment with topiramate may improve negative symptoms in schizophrenia when added to typical antipsychotic drugs (APDs) but not to clozapine. Both dopaminergic and glutamatergic transmissions in the medial prefrontal cortex (mPFC) are facilitated ... Read more...

C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity.

29 Sep 2009 The C957T polymorphism of the human dopamine D2 receptor gene (DRD2) regulates DRD2 availability in striatum in vivo. Specifically, the T allele predicts high DRD2 availability in healthy volunteers (T/T>T/C>C/C). However, this finding was ... Read more...

Latest indexed articles for 'Raclopride'

These are the very latest articles for this heading:

• Ex vivo [11C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro. 30 Oct 2009
• Differential effects of topiramate on prefrontal glutamatergic transmission when combined with raclopride or clozapine. 29 Sep 2009
• C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. 29 Sep 2009
• Acute neurobehavioral effects of toluene: involvement of dopamine and NMDA receptors. 14 Sep 2009
• Evaluating dopamine reward pathway in ADHD: clinical implications. 7 Sep 2009
• Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. 30 Aug 2009
• Dopaminergic activity in depressed smokers: a positron emission tomography study. 30 Jul 2009
• Multitracer assessment of dopamine function after transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson's disease. 29 Jun 2009
• [(3)H]-YM-09151-2 binding sites in human brain postmortem. 16 Jun 2009
• Can recreational doses of THC produce significant dopamine release in the human striatum? 15 Jun 2009
• Abnormal striatal and thalamic dopamine neurotransmission: Genotype-related features of dystonia. 14 Jun 2009
• Quantitative evaluation of changes in binding potential with a simplified reference tissue model and multiple injections of [11C]raclopride. 7 Jun 2009
• Pharmacological characterization of harmaline-induced tremor activity in mice. 31 May 2009
• The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO. 30 May 2009
• Motion correction of multi-frame PET data in neuroreceptor mapping: simulation based validation. 25 May 2009
• Cue-induced dopamine release predicts cocaine preference: positron emission tomography studies in freely moving rodents. 11 May 2009
• Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA. 29 Apr 2009
• Transcription factor SP4 is a susceptibility gene for bipolar disorder. 7 Apr 2009
• Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Apr 2009
• Long-term stability of measuring D(2) receptors in schizophrenia patients treated with antipsychotics. 30 Mar 2009

See a longer list of these articles.

Technical information about 'Raclopride'

Definition: A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.

Chemical name: Benzamide, 3,5-dichloro-N-((1-ethyl-2-pyrrolidinyl)-methyl)-2-hydroxy-6-methoxy-

Registry Number: 84225-95-6

Descriptor UI: D020891

Alternative terms: Raclopride; FLB-472; FLB 472; FLB472; Raclopride C11; C11, Raclopride; FLA-870; FLA 870; FLA870;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antipsychotic Agents; Dopamine Antagonists;

Tree Number: D02.065.277.761; D02.241.223.100.120.761;

History Note: 2000; use RACLOPRIDE 1985-1999